See more : TOW Co.,Ltd. (4767.T) Income Statement Analysis – Financial Results
Complete financial analysis of Psyence Group Inc. (PSYGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psyence Group Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Fuyo General Lease Co., Ltd. (8424.T) Income Statement Analysis – Financial Results
- JGC Holdings Corporation (1963.T) Income Statement Analysis – Financial Results
- ITC Limited (ITC.BO) Income Statement Analysis – Financial Results
- Seibu Giken Co.,Ltd. (6223.T) Income Statement Analysis – Financial Results
- News World Wu Company (2245.TWO) Income Statement Analysis – Financial Results
Psyence Group Inc. (PSYGF)
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.93K | 92.27K | 52.64K | 24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.58M | 2.30M | 115.94K | 21.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.43M | 3.32M | 4.19M | 92.51K | 19.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 152.16K | 253.62K | 146.62K | 131.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.58M | 3.58M | 4.34M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Other Expenses | 0.00 | 5.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Cost & Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Interest Income | 3.57K | 7.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 72.63K | 123.14K | 1.39K | 1.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.93K | 92.27K | 52.64K | 24.50K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K |
| EBITDA | -5.17M | -5.88M | -4.46M | -3.80M | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.16M | -6.09M | -4.59M | -92.51K | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.28M | -208.35K | -145.07K | -13.45M | 0.00 | 32.50K | 4.00 | 4.00 | -46.00 |
| Income Before Tax | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.18K | -83.90K | -8.12M | -206.29K | -171.86K | -161.14K | -52.52K | -22.82K |
| Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| EPS Diluted | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
| Weighted Avg Shares Out (Dil) | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence...
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd....
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agreement (the “Purchase Agreement”) with White Lion Capital, LLC,...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical...
Why Is Psyence Biomedical (PBM) Stock Up 163% Today?
Psyence Biomedical (NASDAQ: PBM ) stock is rocketing higher on Thursday after providing investors with export and clinical trial updates. Starting with its exports, Psyence Biomedical notes that it is shipping nature-derived psilocybin to Australia.
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Trial projected to be initiated shortly following receipt of drug product by trial sites NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the export of nature-derived psilocybin to...
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that it received a notification letter dated June 27, 2024, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”)...
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21,...
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence...
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the "Transaction"), Psyence is...
Source: https://incomestatements.info
Category: Stock Reports